Philip J. Ferneau, M.B.A., J.D., joined the Compass Board of Directors in June of 2015. Mr. Ferneau is co-founder and serves as managing partner of Borealis Ventures ( Borealis ), a venture capital firm focused on healthcare opportunities, a position he has held since 2002. Mr. Ferneau currently leads Borealis investments in Adimab, LLC, Triveni Bio, Inc., Ankyra Therapeutics, Inc., Evox Therapeutics Ltd, Orbit Discovery Ltd, Ovation.i.o, Inc., Teckro Limited, and T-Cypher Bio Limited. Mr. Ferneau was also responsible for the firm s prior investments in Avedro, Inc. (IPO, then acquired by Glaukos Corporation (NYSE: GKOS)), Avitide, Inc. (acquired by Repligen Corporation (Nasdaq: RGEN)), GlycoFi, Inc. (acquired by Merck & Co., Inc. (NYSE: MRK)), M2S (acquired by AIG Altaris Health Partners), and Vets First Choice, Inc. (now Covetrus, Inc.: formerly Nasdaq: CVET, now private). Mr. Ferneau received an A.B. degree from Dartmouth College, a J.D. from the University of Virginia School of Law and an M.B.A. (with High Distinction) from the Tuck School of Business at Dartmouth. We believe that Mr. Ferneau is qualified to serve on our Board of Directors based on his extensive investment and life sciences industry experience.